Table 1

Baseline characteristics of the intention-to-treat (ITT) population with osteoarthritis of the knee

Risedronate


Characteristic

Placebo (n = 98)

5 mg/day (n = 96)

15 mg/day (n = 90)

P


Age (years)

63.2 (0.82)

62.9 (0.90)

63.8 (0.88)

0.652a

Height (cm)

164.3 (0.90)

165.3 (0.97)

165.1 (0.93)

0.614a

Body mass index (kg/m2)

29.2 (0.38)

29.0 (0.40)

29.2 (0.42)

0.799a

Sex (no. (%))

0.307b

Male

34 (35%)

40 (42%)

41 (46%)

Female

64 (65%)

56 (58%)

49 (54%)

Post-menopausal (no. (%))

54 (84%)

49 (88%)

43 (88%)

0.985b

Years since menopause

14.4 (1.22)

16.5 (1.57)

17.4 (1.42)

0.273a

Oestrogen or SERM use (no. (%))

18 (28%)

15 (27%)

10 (20%)

0.380b

Race (no.)

0.385b

Asian Oriental

1

0

0

Asian Indian

1

0

2

Caucasian

96

96

88

Joint-space width (mm)

3.03 (0.05)

2.95 (0.05)

3.01 (0.06)

0.577a

WOMAC – weighted total score

50.3 (2.0)

46.1 (2.0)

49.4 (2.4)

0.281a

Use of walking aids (no. (%))

16 (16)

22 (23)

12 (13)

0.224b

uCTX-II (ng/mmol creatinine)

312.5 (19.9)

328.9 (29.7)

340.1 (24.0)

0.748a

uNTX-I (nmol/mmol creatinine)

40.3 (2.8)

42.3 (4.5)

38.6 (2.2)

0.954a


Unless indicated otherwise, values are means (standard errors of the mean). aKruskal–Wallis test; bFisher exact test. SERM, selective oestrogen receptor modulator; uCTX-II, urinary C-terminal crosslinking telopeptide of type II collagen; uNTX-I, urinary N-terminal crosslinking telopeptide of type I collagen; WOMAC, Western Ontario and McMaster Universities osteoarthritis index.

Spector et al. Arthritis Research & Therapy 2005 7:R625-R633   doi:10.1186/ar1716

Open Data